Developer docs
API playgroundTry for free, no card

Search company profiles

Specific Biologics

Full company profile

uuid0006x81

Namestring
Specific Biologics
Legal namestring
Specific Biologics Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Specific Biologics Inc. is a Toronto-based, venture-backed preclinical biotechnology company developing the Dualase® platform, a novel class of dual-cutting genome editing enzymes that overcome key limitations of single-cut CRISPR-Cas9 systems. The Dualase architecture combines a programmable I-TevI domain with an engineered Cas domain to produce two site-specific DNA cuts (sticky and blunt ends), which biases cellular repair toward precise outcomes, including scarless insertions, deletions, and base changes via a polymerase theta-mediated RNA-templated pathway. The platform's small (~3.7kb) cargo fits within a single adeno-associated virus (AAV) or can be delivered as small RNAs in lipid nanoparticles (LNPs), enabling broad in vivo therapeutic applicability across CNS, lung, liver, and skeletal muscle tissues.

The company's preclinical pipeline targets repeat expansion disorders (e.g., ALS/C9ORF72, Huntington's Disease) via single AAV delivery to the CNS, cystic fibrosis via a proprietary nebulized LNP formulation for lung delivery, and liver indications via LNP-encapsulated RNA. A machine learning-enabled prediction platform is being co-developed with Western University under a CAD$1.8M Genome Canada/Ontario Genomics grant to accelerate identification of new Dualase editors. Specific Biologics is funded by Lumira Ventures and adMare BioInnovations (seed, December 2021; renewed 2023) and has received non-dilutive awards from the Cystic Fibrosis Foundation Therapeutic Development Award (2021).

The business model is structured for long-horizon value creation through eventual commercialization of Dualase-based therapeutics and/or platform licensing to pharmaceutical partners for co-development in additional indications. Near-term, the company is pre-revenue with 1–10 employees and pursues business development outreach, academic collaborations (Western University), and non-dilutive grant funding to advance pipeline assets toward IND-enabling studies.

Short descriptiontext

Specific Biologics is a Toronto-based preclinical biotech developing the Dualase® dual-cut genome editing platform for in vivo treatment of genetic diseases, with initial pipeline programs in CNS neurodegeneration, cystic fibrosis, and liver indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene editing therapeutics, genome editing platform, in vivo gene therapy, repeat expansion disorders, biopharmaceutical development
Industry4 codes
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Product Sales
TypeOne Time License
Description

Pre-revenue biotech company developing gene editing therapies. Revenue model would be through commercialization of Dualase-based therapeutics for genetic diseases once approved by regulatory authorities.

specificbiologics.com
2Platform Licensing
TypeLicensing Royalties
Description

Potential licensing of Dualase platform technology to pharmaceutical partners for development of gene editing therapeutics in additional indications.

specificbiologics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Specific Biologics is a preclinical biotechnology company developing the Dualase® genome editing platform, a novel class of enzymes that make two targeted DNA cuts using an I-TevI domain and an engineered Cas domain. The company is advancing a pipeline of in vivo gene editing therapeutics focused on precise removal of pathogenic DNA repeats in CNS, cystic fibrosis (lung), and liver indications, with delivery via single AAV or lipid nanoparticle encapsulated RNAs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • No detectable off-target effects in vitro or in vivo using targeted and genome-wide surveys
+2 more records
Product overview1 text field

Specific Biologics is developing a single unified platform called Dualase® for gene editing therapeutics. The Dualase platform offers two distinct mechanisms of action: (1) precise sequence removal using dual-guided I-TevI domains for large repetitive sequences delivered via single AAV or small RNAs, and (2) repair or insertion of small or large sequences using RNA-templated DNA repair through polymerase theta. The company's pipeline includes programs targeting neurodegeneration (CNS), cystic fibrosis (lung), and liver diseases, with additional discovery-stage candidates in skeletal muscle and other indications.

Product and service1 record
1Dualase®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Research partnership with Dr. David Edgell's team at Western University to develop machine learning-enabled prediction platform for Dualase genome editors, integrating large-scale genomic datasets and structural modeling. Research team will build computational platform to identify potent Dualase editors for new therapeutic targets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage in vivo CRISPR-Cas9 gene editing company with programs in transthyretin amyloidosis, hereditary angioedema, and hemophilia. Competes for the same in vivo gene editing opportunity and pharma partnering attention.

TypeEmerging player
Description

Preclinical/early-clinical RNA editing and gene therapy company developing programmable editors for repeat expansion disorders and other genetic diseases. Overlap with Specific Biologics' CNS repeat removal program.

TypeDirect peer
Description

Clinical-stage developer of prime editing, a precise gene editing modality that — like Dualase — aims to make targeted insertions, deletions, and base changes without double-strand breaks. Closest mechanistic analog given scarless repair approach.

TypeDirect peer
Description

Clinical-stage CRISPR-Cas9 and Cas12a gene editing company with both in vivo and ex vivo programs. Direct competitor in CNS (e.g., LCA10) and other genetic disease indications.

TypeBroad incumbent
Description

Large biopharma with established cystic fibrosis franchise (Trikafta/Kaftrio) and a partnered CRISPR Therapeutics in vivo program (CTX001 → Casgevy). Most relevant incumbent because of CF indication overlap and proven willingness to partner on gene editing.

TypeDirect peer
Description

Clinical-stage biotech developing in vivo base editing therapeutics for genetic diseases. Most direct competitor to Specific Biologics given overlapping approach to precise in vivo gene correction, with multiple programs already in the clinic.

TypeDirect peer
Description

Pioneer CRISPR-Cas9 therapeutic developer with approved Casgevy (sickle cell, beta-thalassemia) and active in vivo programs. Sets the competitive benchmark for the gene editing space and likely acquirer/partner.

TypeEmerging player
Description

Clinical-stage RNA editing company targeting repeat expansion disorders including Huntington's Disease and ALS. Direct overlap with Specific Biologics' CNS neurodegeneration program and likely competitor for partnership capital.

TypeEmerging player
Description

Gene writing company developing technologies to make precise insertions, deletions, and replacements in the genome. Competes conceptually with Dualase's RNA-templated DNA repair approach for scarless sequence insertion.

TypeDirect peer
Description

Clinical-stage in vivo base editing company focused on cardiovascular disease, with lead programs in familial hypercholesterolemia. Competes with Specific Biologics' liver-directed base-change correction approach.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Specific Biologics

Biopharmaceuticalsspecificbiologics.com

Specific Biologics is a Toronto-based preclinical biotech developing the Dualase® dual-cut genome editing platform for in vivo treatment of genetic diseases, with initial pipeline programs in CNS neurodegeneration, cystic fibrosis, and liver indications.

What Specific Biologics does

Specific Biologics Inc. is a Toronto-based, venture-backed preclinical biotechnology company developing the Dualase® platform, a novel class of dual-cutting genome editing enzymes that overcome key limitations of single-cut CRISPR-Cas9 systems. The Dualase architecture combines a programmable I-TevI domain with an engineered Cas domain to produce two site-specific DNA cuts (sticky and blunt ends), which biases cellular repair toward precise outcomes, including scarless insertions, deletions, and base changes via a polymerase theta-mediated RNA-templated pathway. The platform's small (~3.7kb) cargo fits within a single adeno-associated virus (AAV) or can be delivered as small RNAs in lipid nanoparticles (LNPs), enabling broad in vivo therapeutic applicability across CNS, lung, liver, and skeletal muscle tissues.

The company's preclinical pipeline targets repeat expansion disorders (e.g., ALS/C9ORF72, Huntington's Disease) via single AAV delivery to the CNS, cystic fibrosis via a proprietary nebulized LNP formulation for lung delivery, and liver indications via LNP-encapsulated RNA. A machine learning-enabled prediction platform is being co-developed with Western University under a CAD$1.8M Genome Canada/Ontario Genomics grant to accelerate identification of new Dualase editors. Specific Biologics is funded by Lumira Ventures and adMare BioInnovations (seed, December 2021; renewed 2023) and has received non-dilutive awards from the Cystic Fibrosis Foundation Therapeutic Development Award (2021).

The business model is structured for long-horizon value creation through eventual commercialization of Dualase-based therapeutics and/or platform licensing to pharmaceutical partners for co-development in additional indications. Near-term, the company is pre-revenue with 1–10 employees and pursues business development outreach, academic collaborations (Western University), and non-dilutive grant funding to advance pipeline assets toward IND-enabling studies.

Specific Biologics firmographics

Firmographics
Name
Specific Biologics
Legal name
Specific Biologics Inc.
Website
https://specificbiologics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Specific Biologics is a Toronto-based preclinical biotech developing the Dualase® dual-cut genome editing platform for in vivo treatment of genetic diseases, with initial pipeline programs in CNS neurodegeneration, cystic fibrosis, and liver indications.
Ownership category
akta.pro rank

Specific Biologics industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Gene editing therapeutics
  • Genome editing platform
  • In vivo gene therapy
  • Repeat expansion disorders
  • Biopharmaceutical development

Where Specific Biologics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Specific Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Therapeutic Product Sales: Pre-revenue biotech company developing gene editing therapies. Revenue model would be through commercialization of Dualase-based therapeutics for genetic diseases once approved by regulatory authorities.
  2. Platform Licensing: Potential licensing of Dualase platform technology to pharmaceutical partners for development of gene editing therapeutics in additional indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Specific Biologics product offering

Product offering

Core offering

Specific Biologics is a preclinical biotechnology company developing the Dualase® genome editing platform, a novel class of enzymes that make two targeted DNA cuts using an I-TevI domain and an engineered Cas domain. The company is advancing a pipeline of in vivo gene editing therapeutics focused on precise removal of pathogenic DNA repeats in CNS, cystic fibrosis (lung), and liver indications, with delivery via single AAV or lipid nanoparticle encapsulated RNAs.

Product overview

Specific Biologics is developing a single unified platform called Dualase® for gene editing therapeutics. The Dualase platform offers two distinct mechanisms of action: (1) precise sequence removal using dual-guided I-TevI domains for large repetitive sequences delivered via single AAV or small RNAs, and (2) repair or insertion of small or large sequences using RNA-templated DNA repair through polymerase theta. The company's pipeline includes programs targeting neurodegeneration (CNS), cystic fibrosis (lung), and liver diseases, with additional discovery-stage candidates in skeletal muscle and other indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dualase®

Quantifiable outcome

  • No detectable off-target effects in vitro or in vivo using targeted and genome-wide surveys
  • +2 more outcomes

Companies that use Specific Biologics

Customer profile

Segments4 records

Ideal customer profiles2 records

Specific Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Specific Biologics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Western UniversitycoreStrategic or Co-development Partner · 18 March 2026Research partnership with Dr. David Edgell's team at Western University to develop machine learning-enabled prediction platform for Dualase genome editors, integrating large-scale genomic datasets and structural modeling. Research team will build computational platform to identify potent Dualase editors for new therapeutic targets.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Specific Biologics competitors and assessment

Company assessment

Direct peers

  • Intellia Therapeutics: Clinical-stage in vivo CRISPR-Cas9 gene editing company with programs in transthyretin amyloidosis, hereditary angioedema, and hemophilia. Competes for the same in vivo gene editing opportunity and pharma partnering attention.
  • Prime Medicine: Clinical-stage developer of prime editing, a precise gene editing modality that — like Dualase — aims to make targeted insertions, deletions, and base changes without double-strand breaks. Closest mechanistic analog given scarless repair approach.
  • Editas Medicine: Clinical-stage CRISPR-Cas9 and Cas12a gene editing company with both in vivo and ex vivo programs. Direct competitor in CNS (e.g., LCA10) and other genetic disease indications.
  • Beam Therapeutics: Clinical-stage biotech developing in vivo base editing therapeutics for genetic diseases. Most direct competitor to Specific Biologics given overlapping approach to precise in vivo gene correction, with multiple programs already in the clinic.
  • CRISPR Therapeutics: Pioneer CRISPR-Cas9 therapeutic developer with approved Casgevy (sickle cell, beta-thalassemia) and active in vivo programs. Sets the competitive benchmark for the gene editing space and likely acquirer/partner.
  • Verve Therapeutics: Clinical-stage in vivo base editing company focused on cardiovascular disease, with lead programs in familial hypercholesterolemia. Competes with Specific Biologics' liver-directed base-change correction approach.

Emerging players

  • Shape Therapeutics: Preclinical/early-clinical RNA editing and gene therapy company developing programmable editors for repeat expansion disorders and other genetic diseases. Overlap with Specific Biologics' CNS repeat removal program.
  • Korro Bio: Clinical-stage RNA editing company targeting repeat expansion disorders including Huntington's Disease and ALS. Direct overlap with Specific Biologics' CNS neurodegeneration program and likely competitor for partnership capital.
  • Tessera Therapeutics: Gene writing company developing technologies to make precise insertions, deletions, and replacements in the genome. Competes conceptually with Dualase's RNA-templated DNA repair approach for scarless sequence insertion.

Broad incumbents

  • Vertex Pharmaceuticals: Large biopharma with established cystic fibrosis franchise (Trikafta/Kaftrio) and a partnered CRISPR Therapeutics in vivo program (CTX001 → Casgevy). Most relevant incumbent because of CF indication overlap and proven willingness to partner on gene editing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Specific Biologics social profiles

Digital presence

Specific Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Specific Biologics leadership team

Management profile

Number of profiles

Profiles8 records

Specific Biologics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Specific Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Specific Biologics

What does Specific Biologics do?

Specific Biologics is a preclinical biotechnology company developing the Dualase® genome editing platform, a novel class of enzymes that make two targeted DNA cuts using an I-TevI domain and an engineered Cas domain. The company is advancing a pipeline of in vivo gene editing therapeutics focused on precise removal of pathogenic DNA repeats in CNS, cystic fibrosis (lung), and liver indications, with delivery via single AAV or lipid nanoparticle encapsulated RNAs.

Is Specific Biologics a public or private company?

Specific Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Specific Biologics founded?

Specific Biologics was founded in 2017. It employs 11 to 50 people.

Where is Specific Biologics based?

Specific Biologics is headquartered in Toronto, Canada, in the North America region.

How does Specific Biologics make money?

Two revenue lines are on record. Therapeutic Product Sales are the primary driver. The others are platform Licensing.

Who are Specific Biologics's main competitors?

Direct peers on record are Intellia Therapeutics, Prime Medicine, Editas Medicine, Beam Therapeutics, CRISPR Therapeutics and Verve Therapeutics. Emerging players are Shape Therapeutics, Korro Bio and Tessera Therapeutics. Vertex Pharmaceuticals is listed as a broad incumbent.

Does Specific Biologics have an API?

No public API is recorded for Specific Biologics.

What industry is Specific Biologics in?

Specific Biologics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BestStartup CanadaCanada Startup Funding November 2026 Week 1: Beacon, Specific Biologics and Budget 2026In week 1 of November 2026, Canadian startups raised $85 million in verified deals, with CPP Investments adding $50 million to Beacon Software and Specific Biologics closing a $35 million Series A. Budget 2026 introduced a capital gains exemption on up to $15 million in gains from eligible Canadian investments, with $715 million in tax relief over four years.Pulse 2.0Specific Biologics Raises $35 Million Series A Led By Hatteras Venture Partners For ALS Gene-Editing TherapySpecific Biologics raised $35 million in a Series A led by Hatteras Venture Partners to advance its Dualase gene-editing therapy for ALS. The funding supports early clinical proof-of-concept in an adaptive Phase I/II trial targeting C9ORF72 mutations. The company aims to move from preclinical to initial human clinical evaluation.The future of tradingSpecific Biologics raises USD 35 million in Series A with Lumira Ventures participationSpecific Biologics closed an oversubscribed $35 million Series A financing led by Hatteras Venture Partners, with participation from existing investors Lumira Ventures and adMare BioInnovations. The biotech company develops precision gene-editing therapies for DNA repeat expansions, and proceeds will advance its lead Dualase therapy through initial clinical biomarker proof-of-concept in patients with C9ORF72-associated ALS.PR NewswireSpecific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALSSpecific Biologics closed a US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures and adMare BioInnovations. The funds will advance its Dualase gene-editing therapy for C9ORF72-associated ALS through initial clinical biomarker proof-of-concept. The company aims to bring a potentially transformative medicine to patients with no approved therapies.PR NewswireSpecific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALSSpecific Biologics closed a US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures and adMare BioInnovations. The funds will advance its Dualase gene-editing therapy for C9ORF72-associated ALS through initial clinical biomarker proof-of-concept. The company aims to bring a potentially transformative medicine to patients with no approved therapies.NewswireSpecific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALSSpecific Biologics closed an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners. Proceeds will advance its Dualase gene-editing candidate through initial clinical biomarker proof-of-concept in C9ORF72-associated ALS patients. The company aims to address the disease at its genetic source.Ivey Business SchoolNew funding advances precision gene-editing technologyGenome Canada and Ontario Genomics have invested $1.8 million to support Western researchers and Toronto-based Specific Biologics in developing machine-learning-accelerated gene-editing tools. The funding will advance the Dualase® technology, a novel class of enzymes designed to make two targeted DNA cuts rather than one, improving accuracy over traditional CRISPR-Cas9 methods. The technology is being explored for amyotrophic lateral sclerosis (ALS), Huntington's disease, and other genetic disorders with limited treatment options.PR NewswireGenome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-basSpecific Biologics Inc. and Western University were awarded a CAD$1.8 million grant from Genome Canada and Ontario Genomics to develop a machine learning-enabled prediction platform for Dualase® genome editors. The computational platform will integrate large-scale genomic datasets and structural modeling to rapidly identify potent editors for treating genetic diseases including ALS and Huntington's Disease. The funding will support the company's lead ALS program moving toward clinical trials while expanding the Dualase® platform to additional repeat expansion diseases.PR NewswireGenome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-basSpecific Biologics Inc. and Western University have been awarded a CAD$1.8 million grant from Genome Canada and Ontario Genomics to develop a machine learning prediction platform for Dualase® genome editors. The computational platform will integrate genomic datasets and structural modeling to rapidly identify potent editors for new therapeutic targets beyond the company's lead ALS program targeting C9ORF72 repeat expansions. CEO Dr. Brent Stead stated the ML tool will dramatically accelerate proprietary Dualase® editor discovery by enabling near-instant computational design before beginning lab experiments.NasdaqGenome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company's Dualase®-basSpecific Biologics Inc. and Western University have been awarded a CAD$1.8 million grant from Genome Canada and Ontario Genomics to develop a machine learning-enabled prediction platform for the company's Dualase® genome editing technology. The computational platform will integrate large-scale genomic datasets and structural modeling to accelerate identification of potent Dualase® editors for new therapeutic targets beyond the lead program targeting C9ORF72 ALS. The funding will support expansion into other high morbidity genetic diseases including Huntington's Disease and other repeat expansion disorders.